Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH17 antagonists(Cadherin-17 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Discovery | China | 01 Aug 2022 | |
| Colorectal Cancer | Discovery | China | 01 Aug 2022 | |
| Lung Cancer | Discovery | China | 01 Aug 2022 | |
| Stomach Cancer | Discovery | China | 01 Aug 2022 |






